Regeneron stock heads into the open after a 0.4 percent gain
Published on 09/21/2026 at 04:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock closed at USD 784.85 on the Nasdaq on September 18, 2026, marking a gain of 0.4 percent against the previous close.
September 18, 2026 in numbers
Regeneron Pharmaceuticals Inc. (ISIN US75886F1075, Nasdaq: REGN) opened Friday’s Nasdaq session near USD 784.85 and finished the day at that level after a modest advance of 0.4 percent, according to Nasdaq closing data. Per market recap data, the Nasdaq Composite index also ended the September 18, 2026 session higher, underscoring that Regeneron’s move came in the context of a firmer broader technology and growth stock environment.
As MarketBeat reported in an analyst update published on September 20, 2026, Regeneron was recently upgraded to a strong-buy rating by Wall Street Zen, a move that highlighted positive sentiment around the shares and followed the latest advance at USD 784.85. In a separate report on September 20, 2026, MarketBeat noted that institutional investor Nykredit A S disclosed a new position in Regeneron Pharmaceuticals, adding another element of support for the stock in the wake of the latest session’s close.
Outlook for today
Today, Regeneron heads into the September 21, 2026 US session without a scheduled earnings release or major corporate event explicitly dated for this trading day in recent investor materials, so attention turns to how the stock trades against the backdrop of the broader Nasdaq and biotechnology sector. According to sector positioning data for biotechnology funds such as AXA Framlington Biotech, where Regeneron represents one of the larger holdings as noted by Trustnet, movements in biotechnology benchmarks and broader risk appetite today may continue to influence Regeneron’s trading after the recent analyst upgrade and institutional interest documented over the weekend.
